Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022

This is how her discovery got to cancer clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In 1996, Carolyn Bertozzi and her lab at UC Berkeley were working to develop a way to image cell-surface glycans: sugar-based macromolecules that coat the surface of cells. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Managing Editor
Table of Contents

YOU MAY BE INTERESTED IN

cGAS, a key innate immune protein, helps regulate cholesterol levels inside cells and influences tumor growth and treatment response, according to a study conducted by researchers at the University of North Carolina Lineberger Comprehensive Cancer Center. The findings shed light on how cancer cells rewire their metabolism—and point to potential new strategies for therapy.
At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study. 
Jacquelyn Cobb
Managing Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login